Medlinker

EqualOcean | Southern Weekly 2022 'China Greenwashing List'

Nine companies have been listed on China's Greenwashing List, drawing wider attention to the issue of greenwashing.

EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）

Private enterprises are actively embracing the transformative era

Pure Global: The International Engine of Medical Technology Globalization

As a pioneer in international regulatory management and clinical solutions, Pure Global has evolved into an indispensable partner for medical technology companies. Through its outstanding data technology, seasoned industry expert team, and transnational capabilities, Pure Global empowers its partners to achieve global growth. Presently, Pure Global's services span more than 25 countries and regions, offering tailored solutions for the entire lifecycle of medical devices.

MGI Tech: Lead Life Science Through Intelligent Innovation

In the dynamic realm of bioscience, MGI Tech Co., Ltd. (MGI) has emerged as a torchbearer, captivating attention with its trailblazing achievements and relentless dedication to innovation.

China's "Top Student" Takes on the "International Exam": United Imaging's Path to Overseas

20 Chinese Companies to Watch in Q1 2023– Healthcare+

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in Q1 2023. The following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, the activity level and the segments in which the startups operate.

Surgerii Robotics: Single-Port Surgical Robots Poised to Transform Surgery

The worldwide surgical robotic market is expected to grow at a booming CAGR of 5.8% during 2022 to 2030, rising from USD 5.05 billion in 2022 to USD 21.41 billion in 2030. Of which, the single-port surgical robots that result in less pain, fewer scars, and quicker recovery, have tremendous up potential.

Pulnovo Medical: Chinese Medical Device Companies are Making Their Voices Heard Globally

‘Chinese medical device companies, represented by Pulnovo Medical, have always pursued medical innovation under the support of policies and capital. They have increasingly improved their technical innovation, strategic planning, and product competitiveness. Navigating the way through a dynamic, ever-changing market, Chinese medical device companies are making their voices heard in the global market.’

Chinese IVD enterprises going global - 10 molecular diagnosis companies to watch

IVD tests are medical devices used to diagnose, monitor, screen and assess predispositions to diseases from assays in a test tube or in a controlled environment outside an organism, contributing to the available medical information of a patient. Molecular diagnosis, as one of the fastest growing segments in IVD, especially during the COVID-19 period, refers to the assessment of a person's health at a molecular level through the detection and measurement of specific genetic si

Chinese Medtech enterprises going global - 10 interventional device makers to watch

The medical devices market continued to generate stellar growth in 2022. With the increasing prevalence of cardiovascular and cerebralvascular disease in China, companies are encouraged to develop and create new innovative solutions. Below, EqualOcean has listed 10 leading interventional medical device companies in vascular or neurology fields with overseas business. We hope this will shed some light on Chinese interventional markets.

Chinese Company Turned the Tables on Domestic Cell Culture Media Market

In this article, EqualOcean mainly introduce the history, competition, lead company, future trend in domestic cell culture media industry.

Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis

‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’

The Era of Digital Health: Smart Medical Wearable Device as An Important Component

This article introduces smart medical wearable devices in China.

Opportunities and Challenges Hidden in the CGT Industry in China

CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.

CAR-T Therapy Market Map in China

The market for cell therapy products such as CAR-T is expected to expand rapidly based on increasing investment from the industry and the implementation of advanced technologies.

China VC Investment List Q4 2022 – Healthcare

For healthcare, we at EqualOcean have identified 20 companies worth watching in Q4 identified by proceedings. We select venture capital investments of over CNY 200 million on average or the equivalent value in USD in a single round.

15 Companies to Watch in December 2022 — Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds and industry events that took place in China's healthcare space in December 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the companies operate.

Is Domestic Substitution the Future Trend for the Chinese Cell Culture Media Market?

The cell culture media industry has developed rapidly in recent years, but foreign enterprises still dominate the Chinese market. Is Domestic substitution the future trend for the Chinese cell culture media market?

2022 China Year-in-Review | Healthcare

2022 has been a tough year for most of the pharmaceutical companies but cold winter will pass eventually. We at EqualOcean presented the 2022 year-in-review in two parts. In the second part, we will list major M&A, product approvals, and strategic collaboration news. It's by no means exhaustive, but it'll shed some light on what's to come

2022 China Year-in-Review | Healthcare

2022 has been a tough year for most of the pharmaceutical companies but cold winter will pass eventually. We at EqualOcean presented the 2022 year-in-review in two parts. In the first part, we will list major financing and IPO news. It's by no means exhaustive, but it'll shed some light on what's to come.